• Your Selections:

Refine Results

date

Topics

Content Type

Tags

Medicare Part D: A First Look at Prescription Drug Plans in 2020

This issue brief provides an overview of the Medicare Part D prescription drug benefit plan landscape for 2020, with a focus on stand-alone drug plans, the largest segment of the Part D market. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D plans available in 2020.

Issue Brief Read More

Analysis Finds Record 3,148 Medicare Advantage Plans Will be Available in 2020

A record 3,148 Medicare Advantage plans will be available across the country as alternatives to traditional Medicare, a new KFF analysis finds. That’s up 15% from last year’s 2,734 plans and results in a typical beneficiary having 28 plans available to them in their local market for the 2020 Medicare…

News Release Read More

Medicare Advantage 2020 Spotlight: First Look

In 2020, more than 22 million Medicare beneficiaries (34%) are enrolled in Medicare Advantage plans, which are mainly HMOs and PPOs offered by private insurers as an alternative to the traditional Medicare program. This data note provides an overview of the Medicare Advantage plans that will be available in 2020, including the variation in the number of plans available by county and plan type. The brief also examines the insurers entering the Medicare Advantage market for the first time and also examines the insurers exiting the market.

Issue Brief Read More

Assessing Drug Price Increases in Medicare Part D and the Implications of Inflation Limits

Some recent proposals to lower prescription drug costs would require drug manufacturers to pay a rebate to the federal government if their prices for drugs covered under Medicare Part B and Part D increase by more than the rate of inflation. As context for understanding these proposals, this data note analyzes changes in list prices for drugs covered by Medicare Part D in recent years compared to changes in the rate of inflation.

Issue Brief Read More

List Prices Increased As Much As 9 Times Faster Than Inflation for 20 of the Top 25 Part D Drugs, Suggesting Potential for Savings Under Proposed Inflation Rebate Policies

A new KFF analysis finds that the list prices for most of the top Medicare Part D drugs by total spending increased as much as nine times the rate of inflation (1.7%) between 2016 and 2017, suggesting recent Congressional proposals targeting such increases could generate savings for Medicare and Part…

News Release Read More

What’s the Latest on Medicare Drug Price Negotiations?

In response to higher drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing Medicare to negotiate the price of prescription drugs. This issue brief provides a short history of this proposal, describes several bills introduced in the 116th Congress to allow government negotiations as well as assessments of potential savings from the Congressional Budget Office (CBO), and considers the prospects for action in the future.

Issue Brief Read More

Medicare Part D Beneficiaries Who Reach the Catastrophic Coverage Limit Can Expect to Pay More Out-of-Pocket for Their Prescription Drugs Next Year

Medicare Part D enrollees with relatively high out-of-pocket expenses can expect see their costs rise in 2020, according to a new KFF analysis. This is mainly due to an increase in how much enrollees will pay out of pocket for their prescription drugs in the Part D benefit coverage gap…

News Release Read More

How Will The Medicare Part D Benefit Change Under Current Law and Leading Proposals?

This brief describes how the Medicare Part D benefit will change in 2020 under current law and proposed changes that would affect what beneficiaries, plans, manufacturers, and Medicare pay for drug costs under Part D in the future.

Issue Brief Read More

The Facts on Medicare Spending and Financing

This issue brief examines the latest facts about Medicare spending and financing, including the most recent historical and projected Medicare spending data from the Centers for Medicare and Medicaid Services Office of the Actuary, the 2019 annual report of the Boards of Medicare Trustees, and the 2019 Medicare baseline and projections from the Congressional Budget Office. It discusses historical and projected spending trends, program financing, Medicare’s financial condition, and the future outlook.

Issue Brief Read More

Data Note: Prescription Drugs and Older Adults

This data note explores the attitudes and experiences of older adults, ages 65 and up, when it comes to prescription drugs and related policy proposals being discussed. Experiences across different demographic groups are explored, such as household income and health status.

Issue Brief Read More

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.